Cardio Diagnostics (CDIO) Competitors $3.68 +0.04 (+1.10%) Closing price 08/22/2025 03:59 PM EasternExtended Trading$3.67 -0.01 (-0.16%) As of 08/22/2025 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CDIO vs. MIRA, NAII, CVKD, LSTA, RLYB, CING, ELEV, AYTU, BCAB, and ADAPShould you be buying Cardio Diagnostics stock or one of its competitors? The main competitors of Cardio Diagnostics include MIRA Pharmaceuticals (MIRA), Natural Alternatives International (NAII), Cadrenal Therapeutics (CVKD), Lisata Therapeutics (LSTA), Rallybio (RLYB), Cingulate (CING), Elevation Oncology (ELEV), Aytu BioPharma (AYTU), BioAtla (BCAB), and Adaptimmune Therapeutics (ADAP). These companies are all part of the "pharmaceutical products" industry. Cardio Diagnostics vs. Its Competitors MIRA Pharmaceuticals Natural Alternatives International Cadrenal Therapeutics Lisata Therapeutics Rallybio Cingulate Elevation Oncology Aytu BioPharma BioAtla Adaptimmune Therapeutics Cardio Diagnostics (NASDAQ:CDIO) and MIRA Pharmaceuticals (NASDAQ:MIRA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, media sentiment, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation. Do analysts rate CDIO or MIRA? Cardio Diagnostics currently has a consensus target price of $60.00, indicating a potential upside of 1,530.43%. MIRA Pharmaceuticals has a consensus target price of $17.00, indicating a potential upside of 1,088.81%. Given Cardio Diagnostics' higher probable upside, research analysts clearly believe Cardio Diagnostics is more favorable than MIRA Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cardio Diagnostics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00MIRA Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Do insiders & institutionals hold more shares of CDIO or MIRA? 8.1% of Cardio Diagnostics shares are owned by institutional investors. Comparatively, 35.2% of MIRA Pharmaceuticals shares are owned by institutional investors. 22.3% of Cardio Diagnostics shares are owned by company insiders. Comparatively, 6.7% of MIRA Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the media refer more to CDIO or MIRA? In the previous week, Cardio Diagnostics and Cardio Diagnostics both had 2 articles in the media. Cardio Diagnostics' average media sentiment score of 0.10 beat MIRA Pharmaceuticals' score of 0.01 indicating that Cardio Diagnostics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardio Diagnostics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral MIRA Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Which has more volatility & risk, CDIO or MIRA? Cardio Diagnostics has a beta of 2.96, indicating that its share price is 196% more volatile than the S&P 500. Comparatively, MIRA Pharmaceuticals has a beta of 1.77, indicating that its share price is 77% more volatile than the S&P 500. Which has higher earnings & valuation, CDIO or MIRA? MIRA Pharmaceuticals has lower revenue, but higher earnings than Cardio Diagnostics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCardio Diagnostics$40K161.92-$8.38MN/AN/AMIRA PharmaceuticalsN/AN/A-$7.85M-$0.49-2.92 Is CDIO or MIRA more profitable? MIRA Pharmaceuticals has a net margin of 0.00% compared to Cardio Diagnostics' net margin of -30,465.10%. Cardio Diagnostics' return on equity of -72.78% beat MIRA Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Cardio Diagnostics-30,465.10% -72.78% -66.17% MIRA Pharmaceuticals N/A -406.70%-328.44% SummaryCardio Diagnostics beats MIRA Pharmaceuticals on 7 of the 12 factors compared between the two stocks. Get Cardio Diagnostics News Delivered to You Automatically Sign up to receive the latest news and ratings for CDIO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CDIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CDIO vs. The Competition Export to ExcelMetricCardio DiagnosticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.42M$3.11B$5.76B$9.58BDividend YieldN/A2.23%4.41%4.10%P/E RatioN/A20.8831.1026.05Price / Sales161.92342.28432.51103.82Price / CashN/A43.1937.7358.48Price / Book0.678.129.536.61Net Income-$8.38M-$54.72M$3.26B$265.56M7 Day Performance1.38%2.63%2.10%1.97%1 Month Performance-16.55%2.78%2.81%-0.36%1 Year Performance-70.94%11.01%30.56%19.03% Cardio Diagnostics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CDIOCardio Diagnostics2.6345 of 5 stars$3.68+1.1%$60.00+1,530.4%-70.8%$6.42M$40K0.001Short Interest ↑MIRAMIRA Pharmaceuticals3.0577 of 5 stars$1.42+2.9%$17.00+1,097.2%-23.5%$23.35MN/A-2.782Analyst UpgradeGap UpNAIINatural Alternatives InternationalN/A$3.70-0.1%N/A-28.5%$22.89M$113.80M-2.66290High Trading VolumeCVKDCadrenal Therapeutics3.2194 of 5 stars$10.94-1.9%$32.00+192.5%+82.2%$22.82MN/A-1.184LSTALisata Therapeutics2.1964 of 5 stars$2.77+6.5%$23.50+748.4%-8.5%$22.76M$1M-1.2430Analyst ForecastRLYBRallybio3.1013 of 5 stars$0.50-6.4%$10.00+1,912.1%-43.1%$22.19M$640K-0.5340Short Interest ↓CINGCingulate2.6737 of 5 stars$4.05-2.9%$26.00+542.0%-63.1%$21.95MN/A-0.4820Earnings ReportAnalyst ForecastShort Interest ↑ELEVElevation Oncology1.4251 of 5 stars$0.37flat$2.62+616.9%N/A$21.62MN/A-0.4540AYTUAytu BioPharma3.149 of 5 stars$2.24-5.5%$10.00+346.4%-10.9%$21.27M$81M-3.11160Gap DownBCABBioAtla2.2968 of 5 stars$0.36+2.8%$5.00+1,279.3%-80.2%$20.60M$11M-0.3360Gap UpADAPAdaptimmune Therapeutics2.119 of 5 stars$0.09+10.7%$1.35+1,475.4%-95.1%$20.54M$178.03M-0.32490Insider TradeGap Up Related Companies and Tools Related Companies MIRA Competitors NAII Competitors CVKD Competitors LSTA Competitors RLYB Competitors CING Competitors ELEV Competitors AYTU Competitors BCAB Competitors ADAP Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CDIO) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cardio Diagnostics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cardio Diagnostics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access